文章：

局部进展期胃癌新辅助与辅助治疗的现状与未来

The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer

原文发布日期：15 August 2023

DOI: 10.3390/cancers15164114

类型: Article

开放获取: 是

英文摘要：

Gastric cancer is a highly prevalent and lethal disease worldwide. Given the insidious nature of the presenting symptoms, patients are frequently diagnosed with advanced, unresectable disease. However, many patients will present with locally advanced gastric cancer (LAGC), which is often defined as the primary tumor extending beyond the muscularis propria (cT3-T4) or having nodal metastases (cN+) disease and without distant metastases (cM0). LAGC is typically treated with surgical resection and perioperative chemotherapy. The treatment of LAGC remains a challenge, given the heterogeneity of this disease, and the optimal multimodal treatment regimen may be different for different LAGC subtypes. However, many promising treatments are on the horizon based on knowledge of molecular subtypes and key biomarkers of LAGC, such as microsatellite instability, HER2, Claudin 18.2, FGFR2, and PD-L1. This review will expand upon the discussion of current standard neoadjuvant and adjuvant therapies for LAGC and explore the ongoing and future clinical trials for novel therapies, with information obtained from searches in PubMed and ClinicalTrials.gov.

摘要翻译： 

胃癌是全球范围内高发且致死率高的疾病。由于早期症状隐匿，患者常被诊断为晚期不可切除的疾病。然而，许多患者就诊时表现为局部进展期胃癌，通常定义为原发肿瘤突破固有肌层（cT3-T4）或存在淋巴结转移（cN+）但无远处转移（cM0）的病变。局部进展期胃癌的标准治疗模式为手术切除联合围手术期化疗。鉴于该疾病的异质性，其治疗仍面临挑战，不同亚型可能需要差异化的最佳多模式治疗方案。随着对局部进展期胃癌分子亚型及关键生物标志物（如微卫星不稳定性、HER2、Claudin 18.2、FGFR2和PD-L1）认知的深入，许多前景广阔的治疗方案正在涌现。本综述基于PubMed和ClinicalTrials.gov的文献检索，将系统阐述当前局部进展期胃癌新辅助与辅助治疗的标准方案，并探讨正在开展及未来针对新型疗法的临床试验。

原文链接：

The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer